Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Thursday. They currently have a $25.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 149.50% from the stock’s previous close.

Separately, ValuEngine raised Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th.

Oramed Pharmaceuticals (NASDAQ ORMP) traded up 4.79% on Thursday, hitting $10.50. The stock had a trading volume of 54,554 shares. The stock’s 50 day moving average is $9.13 and its 200 day moving average is $7.97. Oramed Pharmaceuticals has a one year low of $5.70 and a one year high of $11.19. The stock’s market cap is $139.86 million.

TRADEMARK VIOLATION WARNING: “Oramed Pharmaceuticals Inc. (ORMP) Stock Rating Reaffirmed by HC Wainwright” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at http://www.mareainformativa.com/oramed-pharmaceuticals-inc-ormp-stock-rating-reaffirmed-by-hc-wainwright/117667/.

In other news, Director Xiaopeng Li acquired 89,636 shares of Oramed Pharmaceuticals stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $8.50 per share, with a total value of $761,906.00. Following the acquisition, the director now owns 206,350 shares in the company, valued at $1,753,975. The transaction was disclosed in a document filed with the SEC, which is available through this link. 27.50% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. Wells Fargo & Company MN grew its stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,725 shares of the biotechnology company’s stock after purchasing an additional 625 shares during the quarter. Wells Fargo & Company MN owned about 0.11% of Oramed Pharmaceuticals worth $114,000 at the end of the most recent reporting period. 1.34% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.